Invest in the Rocky Mountain Region

• Meet one-on-one with top bioscience companies in the Rocky Mountain region.
• Evaluate fresh investment opportunities

Over $1.2 billion in investment in the region (2011-2013 Totals)
Colorado        $787.4M
Utah               $184.7M
Arizona          $130.2M
New Mexico  $96.8M
Montana         $3M


Notable Acquisitions in the Rocky Mountain Region (2010-2014):

  • Ulthera acquired by Merz Aesthetics — $600M
  • Alpine Bioscience acquired by Oncothyreon — $27M
  • Inviragen acquired by Takeda — $250M
  • Lanx acquired by Biomet —$147M
  • LigoCyte acquired by Takeda — $60M
  • CaridianBCT acquired by  Terumo Corp. — $2.63B
  • Baxa acquired by Baxter —$380M
  • Medivance acquired by CR Bard — $230M
  • Abraxis Bioscience acquired by Celgene — $2.9M